NEURONETICS, INC.

Analyst Reco. Neuronetics, Inc.

Equities

STIM

US64131A1051

Delayed Nasdaq Other stock markets 14:32:53 29/04/2024 BST			5-day change	1st Jan Change
3.57 ^USD	+2.29%		-4.55%	+23.10%

04-10	Neuronetics, Inc. Announces the Publication of Significant Clinical Findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation	CI
03-28	Neuronetics, Inc. Announces John K. Bakewell, Joseph H. Capper and Dr. Wilfred E. Jaeger Not Stand for Reelection to the Board	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Canaccord Genuity Adjusts Price Target on Neuronetics to $7 From $9, Maintains Buy Rating	08/03/23	MT
Piper Sandler Adjusts Neuronetics' Price Target to $9 From $10, Reiterates Overweight Rating	03/01/22	MT
NEURONETICS : JMP Securities Adjusts Price Target on Neuronetics to $12 From $18, Maintains Market Outperform Rating	14/10/21	MT
NEURONETICS : William Blair Downgrades Neuronetics to Market Perform From Outperform	13/10/21	MT
NEURONETICS : BTIG Downgrades Neuronetics to Neutral from Buy	13/10/21	MT
NEURONETICS : William Blair Upgrades Neuronetics to Outperform From Market Perform	22/01/21	MT
NEURONETICS : Piper Sandler Adjusts Neuronetics' Price Target to $27 from $20, Keeps Overweight Rating	21/01/21	MT
NEURONETICS : BTIG Research Adjusts Neuronetics PT to $21 From $14, Maintains Buy Rating	21/01/21	MT
NEURONETICS : BTIG Research Adjusts Neuronetics PT to $14 From $10, Maintains Buy Rating	07/12/20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer